Paper · 42983403
Efficacy of anti-PD-1/PD-L1 plus chemotherapy in treatment-naïve advanced HER2-negative gastric adenocarcinoma among different PD-L1 intervals: an updated meta-analysis and reconstructed individual patient-level data analysis.
Chen YK and 8 others. BMC Med, 2026.
11 sourcespapers-2026-11-12-0.1.0
Cite this record
ConductScience Library. Efficacy of anti-PD-1/PD-L1 plus chemotherapy in treatment-naïve advanced HER2-negative gastric adenocarcinoma among different PD-L1 intervals: an updated meta-analysis and reconstructed individual patient-level data analysis. Papers, record 42983403. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/42983403
On this page
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
Efficacy of anti-PD-1/PD-L1 plus chemotherapy in treatment-naïve advanced HER2-negative gastric adenocarcinoma among different PD-L1 intervals: an updated meta-analysis and reconstructed individual patient-level data analysis.
- Journal
- BMC Med
- Year
- 2026
- Publication types
- Journal Article, Meta-Analysis
- Revised in PubMed
- 2026-11-06
Source PubMed
Topics9
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Stomach Neoplasms | Major topic |
| Adenocarcinoma | Major topic |
| Programmed Cell Death 1 Receptor | Major topic |
| Immune Checkpoint Inhibitors | Major topic |
| B7-H1 Antigen | Major topic |
| Antineoplastic Combined Chemotherapy Protocols | Major topic |
| Humans | |
| Erb-b2 Receptor Tyrosine Kinases | |
| Treatment Outcome |
Source PubMed
Grants6
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| 82203299 | National Natural Science Foundation of China | PubMed | ||
| 82303866 | National Natural Science Foundation of China | PubMed | ||
| 82473362 | National Natural Science Foundation of China | PubMed | ||
| GZC20230961 | Postdoctoral Fellowship Program of China Postdoctoral Science Foundation | PubMed | ||
| 2024A1515012980 | Natural Science Foundation of Guangdong Province | PubMed | ||
| 2023QNRC001 | Young Elite Scientists Sponsorship Program by CAST | PubMed |
Source PubMed
Trials0
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
None in this release.
Comments and corrections0
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
None in this release.
References36
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 18,097,448 | Immunological aspects of cancer chemotherapy. | Nat Rev Immunol | 2008 | https://conductscience.org/library/papers/18097448 | PubMed |
| 2 | 37,666,264 | First-line regorafenib with nivolumab and chemotherapy in advanced oesophageal, gastric, or gastro-oesophageal junction cancer in the USA: a single-arm, single-centre, phase 2 trial. | Lancet Oncol | 2023 | https://conductscience.org/library/papers/37666264 | PubMed |
| 3 | 22,297,116 | Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves. | BMC Med Res Methodol | 2012 | https://conductscience.org/library/papers/22297116 | PubMed |
| 4 | 38,806,195 | Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first line treatment for advanced gastric or gastro-oesophageal junction adenocarcinoma: RATIONALE-305 randomised, double blind, phase 3 trial. | BMJ | 2024 | https://conductscience.org/library/papers/38806195 | PubMed |
| 5 | 33,538,338 | Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. | CA Cancer J Clin | 2021 | https://conductscience.org/library/papers/33538338 | PubMed |
| 6 | 30,132,118 | Evaluation of classical clinical endpoints as surrogates for overall survival in patients treated with immune checkpoint blockers: a systematic review and meta-analysis. | J Cancer Res Clin Oncol | 2018 | https://conductscience.org/library/papers/30132118 | PubMed |
| 7 | 34,454,674 | Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study. | Lancet | 2021 | https://conductscience.org/library/papers/34454674 | PubMed |
| 8 | 39,357,127 | Gastric cancer-Epidemiology, modifiable and non-modifiable risk factors, challenges and opportunities: An updated review. | Cancer Treat Res Commun | 2024 | https://conductscience.org/library/papers/39357127 | PubMed |
| 9 | 35,241,494 | Efficacy and predictive biomarkers of immunotherapy in Epstein-Barr virus-associated gastric cancer. | J Immunother Cancer | 2022 | https://conductscience.org/library/papers/35241494 | PubMed |
| 10 | 33,792,646 | Assessment of Pembrolizumab Therapy for the Treatment of Microsatellite Instability-High Gastric or Gastroesophageal Junction Cancer Among Patients in the KEYNOTE-059, KEYNOTE-061, and KEYNOTE-062 Clinical Trials. | JAMA Oncol | 2021 | https://conductscience.org/library/papers/33792646 | PubMed |
1 to 10 of 36
See all 36 referencesCited by0
The papers in our copy of PubMed whose reference list names this one, newest first.
None in this release.
Genes0
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
None in this release.
Drugs0
The drugs whose trials, in the Pipelines release, list the paper.
None in this release.
Data0
The data bank entries PubMed's record names. Trial numbers are under Trials.
None in this release.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/42983403
GET https://conductscience.org/api/papers/v1/42983403/references?page=2